SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 ...
Assessment of programmed cell death ligand 1 (PD-L1) immunohistochemical staining is used for decision on treatment with programmed cell death 1 and PD-L1 checkpoint inhibitors in lung adenocarcinomas ...
F. Hoffmann-La Roche Ltd / Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 22C3 pharmDx as a companion ...
Hematogenix, an industry leader in the field of integrated pathology services for drug development and clinical testing, announces the availability of the FDA approved PD-L1 companion diagnostic ...
FDA Approves PD-L1 Companion Diagnostic in Triple-Negative Breast Cancer This past Friday, Agilent Technologies announced it has received approval by the FDA for the use of PD-L1 IHC 22C3 pharmDx as ...
Modulation of the human immune system to recognize tumor cells is the underlying principle behind cancer immunotherapy. Over the past several years drug manufacturers have seen amazing success with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback